Plain-English translation of NCT07695701 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called acoramidis to see how well it helps people with a rare heart disease caused by amyloid protein buildup. The study will track changes in your heart's structure and function over three years using heart imaging scans and ultrasounds. Researchers want to understand if this medication can improve how your heart works and reduce the amyloid buildup affecting it.
Amyloid cardiomyopathy is a serious condition where abnormal protein deposits damage the heart, and there is a need to find treatments that can slow or reverse this damage. This trial aims to show whether this medication can meaningfully improve heart health and quality of life for people living with this condition.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth twice daily for three years. You'll visit the clinic at the start, after four weeks, at six months, and every six months after that, plus phone check-ins at three months and periodically thereafter. During clinic visits, you'll have heart imaging tests (MRI and ultrasound) and blood work to see how the medication is affecting your heart. The entire study, including follow-up, will last about 38 months.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Eidos Therapeutics, a BridgeBio company
Enrollment target
~150 participants
Started
July 2026
Primary completion
August 2030
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Medical Information
Eidos Therapeutics, a BridgeBio company
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.